ReviewCancers2022
Changes in the Epidemiology of Hepatocellular Carcinoma in Asia.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma.ESMO open · 2026Guideline
- Spatiotemporal heterogeneity of neutrophil extracellular traps in hepatocellular carcinoma microenvironment and targeted therapy progress.Journal of translational medicine · 2026Review
- Multi-scale computational analysis of monoacylglycerol lipase inhibition as a new therapeutic strategy for hepatocellular carcinoma.Scientific reports · 2026Article
- A Scoping Review and Risk Assessment of Aflatoxin B1 Contamination in Rice, Maize, and Peanut-Based Products Across Selected ASEAN Countries.Foods (Basel, Switzerland) · 2026Review
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Genetic variants underlying precancerous conditions of hepatocellular carcinoma.International journal of cancer · 2026Review
- Risk Scores for Stratifying Hepatocellular Carcinoma and Optimizing Surveillance Strategies.Cancers · 2026Review
- Hepatocellular Carcinoma Precursor Lesions: From Pathological Basis to Risk Stratification and Precision Intervention.Journal of hepatocellular carcinoma · 2026Review
- Mimulone-induced Apoptosis through the Extrinsic Pathway and ERK Inactivation in Human Hepatoma Hep3B Cells.Cell biochemistry and biophysics · 2025Article
- Glutamine reprogramming affects the tumor microenvironment and immune response in hepatocellular carcinoma.Molecular biology reports · 2025Review
- Minimal clinical predictors enable machine learning detection of hepatocellular carcinoma in a Filipino cohort.Scientific reports · 2025Article
- Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.The Lancet regional health. Europe · 2025Review
- Bangkok declarations on cancer control in Asia.The Lancet regional health. Western Pacific · 2025Review
- Liver disease trends in the Asia-Pacific region for the next 50 years.Clinical and molecular hepatology · 2025Review
- Article
- Unlocking the Potential of Radiofrequency Ablation in Treating Hepatocellular Carcinoma Among Elderly Patients: A Literature Review.Acta medica academica · 2025Review
- Increasing Prevalence of Occult HBV Infection in Adults Vaccinated Against Hepatitis B at Birth.Vaccines · 2025Article
- Prediction of Hepatocellular Carcinoma Prognosis and Immunotherapy Response Using Mitochondrial Dysregulation Features.Journal of cellular and molecular medicine · 2025Article
- Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.Belitung nursing journal · 2025Article
- Phylodynamics of hepatitis B virus genotype B in East Asia: A population genomics analysis.Journal of biological methods · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with high morbidity and mortality, and the incidence is on the rise. HCC imposes a heavy healthcare burden on Asian countries due to the presence of multiple HCC risk factors in this area. Chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, non-alcoholic liver disease (NAFLD), aflatoxin and alcohol intake are the causes of HCC that cannot be ignored. Compared with the pre-vaccination era, universal vaccination of newborns reduces the incidence of HCC. Anti-viral therapy with nucleos(t)ide analogues also causes a decline in HCC incidence. Early screening and direct-acting antiviral agent are beneficial to the prevention and treatment of HCV. For HCC caused by NAFLD and other reasons, lifestyle changes are imperative. This paper introduces the epidemiological trends of HCC in Asia and highlight future efforts. Focusing on prevention may be the most effective way to improve the prognosis of this hard-to-treat cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.